Fatigue or ageing is blamed when breath gets short or legs feel heavy after mild physical activity ... a harmless part of getting older. Known as arcus senilis, it’s made of lipid (fat) deposits.

Addepar, the data platform for wealth, investment, and asset management, announced the acquisition of Arcus, an enterprise AI workflow platform. Terms of the transaction were not disclosed. “Addepar ...

Also generating attention is new data on a HIF-2α inhibitor from US biotech Arcus Biosciences (NYSE ... and adverse events were consistent with known risks, including mild headache and fatigue. CIT ...

Arcus acquired a majority stake in FixMap in September Net is the second add-on under Arcus’ ownership FixMap is a Polish FTTH operator founded in 2018 Arcus Infrastructure Partners portfolio ...

All adverse events were mild (grade 1 or 2 ... with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and ...

Symptoms of RVO can vary from mild to highly apparent. The clinic states ... there are a couple of less common signs of high cholesterol that may affect the eyes. Corneal arcus is visible as a grey or ...

Arcus Biosciences (NYSE:RCUS) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Arcus ...

If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. With 51% stake, institutions possess the maximum shares ...

Internet Union is the first acquisition under AEIF3’s ownership Arcus acquired a majority stake in FixMap in September The transaction will increase FixMap’s portfolio to around 387k homes ...

A new report out today from anti-ransomware and cyber resilience platform provider Halcyon Tech Inc. details the increasingly sophisticated techniques used by the Arcus Media ransomware group.

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1 ...